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Splinting for thumb carpometacarpal osteoarthritis: protocol for a feasibility 
randomised controlled trial  
Background: Evidence for the use of splints to reduce pain and improve function and quality of 
life in thumb carpometacarpal osteoarthritis (CMC OA) is sparse and poor despite 
recommendations by international guidelines.  
Objective: To outline the protocol for a study designed to determine the feasibility of conducting 
a fully powered pragmatic randomised controlled trial (RCT) comparing soft splint vs no splint for 
thumb CMC OA.  
Methods: The proposed pragmatic, assessor-blinded, and partial participant blinded parallel-
group feasibility RCT will recruit 30 adults with thumb CMC OA and randomise to: splint 
intervention or usual care control. Randomisation will be stratified by hand dominance. Primary 
feasibility outcomes are recruitment rate over a 4-month period, retention rate at 6 months, 
intervention acceptability, and rate of adverse events. Study costs, intervention fidelity, and 
clinical outcomes will also be evaluated. Measurements will be collected at baseline, 4 weeks, 
and 6 months post-initiation of treatment. This trial has been registered with the Australian New 
Zealand Clinical Trials Registry (ANZCTR): ACTRN12618001639213. 
Major Findings: N/A 
Conclusions: If shown to be effective, soft off-the shelf splints would be a good first-line non-
pharmacological, non-surgical option for thumb CMC OA as prescribed by health professionals 
or accessed directly by patients. This feasibility study will inform a future, fully powered RCT as 
evaluated by success of the recruitment strategy; assessment time and acceptability; 
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Symptomatic thumb carpometacarpal osteoarthritis (CMC OA) has an estimated age-adjusted 
prevalence of 22% in the UK community-dwelling population aged 50 years and over [1]. In the 
Swedish population aged 20 years and over, the rate of doctor-diagnosed thumb CMC OA is 1.4%, 
with prevalence 3-4 times higher in women than in men [2]. Over a 15-year period, one in 20 
Swedish women presented to a physician with thumb CMC OA. In a North American population, 
the life time risk of developing symptomatic hand OA by age 85 is 40% [3]; the thumb CMC joint 
is the single most commonly affected site [1, 4] and contributes more to pain and disability in hand 
OA than other hand joints [4, 5]. Thumb CMC OA presents a substantial individual and societal 
burden and an aging population heralds a rapidly rising prevalence.  
We recently completed a qualitative study to investigate the perspectives of patients with thumb 
CMC OA and identified the following key concerns: pain that interrupts sleep; limited ability to 
perform power grip and precision tasks; and limited ability to participate in work, caregiving, 
recreational and physical activities, and activities of daily living. Negative thoughts and feelings 
included frustration, anger, worry, concern about the future, and the burden of medication; and an 
altered sense of self, related to ageing [6]. Impact was greater where the dominant hand was 
involved [6].  
Despite the high prevalence and significant impact of thumb CMC OA, there is a lack of high-
quality evidence to support clinicians, patients, and policy makers in decision-making about 
interventions for the condition. Surgical intervention can provide relief but is usually reserved as 
the last option; joint replacement has not proven as successful as that for hip or knee OA [7, 8]. 
Pharmacological treatments carry risk such as adverse gastrointestinal, cardiovascular, and renal 
events resulting from nonsteroidal anti-inflammatory drugs, especially in the older population [9], 
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and injection therapies have not shown demonstrable efficacy [10]. Therefore, interventions that 
reduce the need for drug therapy or surgical intervention are highly desirable. Splinting is a non-
pharmacological, non-surgical, biomechanical intervention to provide external support to the CMC 
joint, to reduce pain, prevent contracture, and maintain hand function [11]. Clinicians commonly 
prescribe splints [12, 13] and previous clinical studies have shown positive results, with significant 
reductions in pain and reduced demand for surgery [14, 15, 16]. However, because the strength 
and quality of the existing published evidence for splinting in thumb CMC OA is variable and 
often of poor quality, international treatment guidelines can make only weak recommendations for 
their use in splints for thumb OA [10, 17]. Although a recent guideline update advocates long-term 
use of splints [18], this is primarily based on an older single study of participants wearing a 
thermoplastic splint at night for 12 months [14, 19], a protocol not widely used nor well aligned to 
currently proposed mechanisms of effect [11, 13, 20, 21, 22].  
The role of biomechanical interventions such as splints has been highlighted as a key area of 
osteoarthritis management in need of more research [7]. Our recent systematic review found splints 
to be a safe intervention; however, only low-quality evidence supports their use, and only in the 
medium-term (3-12 months) [20]. Furthermore, splints are made from a variety of materials and 
designs; currently, there appears to be no difference between splint types although this is based on 
very low-quality evidence [20].  
One possible splinting solution is a soft neoprene splint, available off–the-shelf and easily fitted, 
making it a cheaper and more accessible option than other splints, and often preferred by patients 
[23, 24]. However, no study comparing a soft, off-the shelf splint with a no-splint control has yet 
been completed [20]. To conduct an effectiveness trial to a high standard, there is a need ensure 
that trial design minimizes research waste and optimizes quality of findings. To achieve this, study 
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elements are best assessed by feasibility study [25, 26]. Therefore, the primary aim of this study is 
to determine the feasibility of conducting a fully powered pragmatic randomised controlled trial 
(RCT) comparing soft splint vs no splint control for thumb CMC OA. 
Specific criteria to determine feasibility are: recruitment of 30 participants in a 4-month period; 
retention >85% at 6 months; >90% find the intervention acceptable; and determine rate of adverse 
events [Table 1].  
Secondary aims are: 1) to confirm the time required for assessor and clinician in the full study; 2) 
achieve intervention implementation in over 80% of prescribed time; 3) satisfactory quality-
control audit of intervention; 4) determine success of recruitment and randomization; 5) explore 
whether treatment effects/outcomes are consistent with expectations based on previous literature. 
Data will be collected and analysed to investigate the impact of the splint vs no splint on patient-
reported pain, function, quality of life, and use of other treatments including medication, and on 
physical performance variables (although due to small sample size these will be preliminary data 
only and unlikely to reach significance). We also aim to explore the potential role of imaging (X-
ray and ultrasound) in evaluating participant characteristics at baseline and the ability of imaging 
to identify a subgroup of participants who may be more responsive to treatment.   
Methods: 
Study design 
Pragmatic, assessor-blinded, and partial participant blinded parallel-group feasibility RCT with 
randomisation stratified by hand dominance. The proposed study will establish the feasibility of 
conducting a fully sized future trial designed to assess the superiority of a soft prefabricated splint 
intervention vs no splint intervention at the 4-week follow up. Measurements will be collected at 
baseline, 4 weeks, and 6 months post-initiation of treatment. The nature of the intervention offered 
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will not be revealed to participants until after the 4-week follow up to avoid bias in how they 
perceive the intervention at the primary end point; i.e. participants will remain blinded to the study 
hypothesis until after the 4-week follow up. The protocol adheres to the SPIRIT 2013 Statement 
[27], which defines standard protocol items for clinical trials, and is informed by the CONSORT 
2010 Statement extension for randomized pilot and feasibility trials [28]. A sample size of 30 
participants is considered sufficient for a feasibility study [29, 30]. 
This trial has been registered with the Australian New Zealand Clinical Trials Registry 
(ANZCTR): ACTRN12618001639213. The trial can be viewed at 
http://www.ANZCTR.org.au/ACTRN12618001639213.aspx 
Setting 
The study will be conducted in health settings in two centres in the South Island of New Zealand 
(Dunedin and Invercargill). A clinical research administrator at the hosting research centre will 
manage recruitment processes and provide administrative support for the study. An independent 
research assistant blinded to participants’ allocation will conduct the baseline, 4-week, and 6-
month assessments. A registered hand therapist/physiotherapist with 17 years clinical experience 
(MB) will implement the intervention.  
Participants 
We aim to recruit adults with symptomatic CMC OA – either physician diagnosed, or history 
suggestive of thumb CMC OA with clinical signs and no other specific diagnosis (Table 2).  
Currently, no specific clinical classification criteria for thumb CMC OA exists. Therefore, an 
accepted method for identifying history suggestive of hip/knee OA [31] will be adapted for use in 
the thumb, along with clinical assessment adapted from the American College of Rheumatology 
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criteria for generalised hand OA [32]. If an eligible participant presents with bi-lateral thumb pain, 
only the self-nominated ‘worst’ thumb will be included.  
Participants will be recruited between April and July 2019 from community and health settings, 
including secondary public health services in the two centres. Recruitment will be by way of 
advertisement or clinician invite. The recruitment strategy will aim to optimize the number of 
indigenous New Zealand Māori participants by recruitment through Māori health providers, 
recruitment of those who may not have previously sought treatment, through newspaper, 
community, and GP adverts, and by recruiting in the second centre of Invercargill where a higher 
proportion of the population are of Māori descent compared to that in Dunedin [33]. Potential 
participants will contact the research administrator for a Patient Information Sheet or download 
this from the study website.   
Randomisation and allocation concealment 
The randomisation schedule will be prepared by the clinical research administrator by 
computerized sequence generation and concealed in series of opaque envelopes according to 
three randomisation blocks (dominant vs nondominant vs ambidextrous). Following the consent 
process and baseline assessment, the next envelope in sequence in the relevant block will be 
opened by the clinician to reveal group allocation. Study procedures are outlined in Figure 1. 
Blinding 
It will not be possible to fully blind participants or the treating clinicians to group allocation due 
to the nature of the study intervention. However, to provide partial blinding, the study hypothesis 
will not be revealed to participants until after the 4-week follow up visit. Information provided to 
participants will explain that the exact nature of the treatments offered to the opposite group will 
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be concealed from them until after the 4-week follow up so that their perceptions about the 
intervention do not influence the study findings at this time period.   
Instruction will be given to the treating therapist, assessors, and all health professionals and 
administration staff involved in participants’ care to conceal this information until after the 4-
week follow up. Outcome assessors will not be involved in participant care and will be blinded 
to group allocation. Participants’ splints will be removed prior to assessment and participants 
will be instructed not to disclose information about their treatment. 
Intervention  
Participants randomized to the intervention group will be fitted with a soft neoprene hand-based 
splint (Procool T/R Splint Bound, @Therapy), issued a second (for one to wash, one to wear) 
and instructed to wear the splint 20 hours out of 24 for 4 weeks. An explanation of the rationale 
and wearing schedule for the splints will be given. 
A simple behavioural intervention will accompany the splint prescription comprising dedicated 
time for skill acquisition and practice within the treatment session for donning and doffing the 
splint; providing feedback and encouragement; and fostering self-efficacy through problem 
solving to incorporate the splint in everyday life [34]. Minor modifications may be made to the 
splint (shorten or alter shape of the thumb exit space by cutting; alter length of strap through web 
space or wrist using NRX Strap, @Therapy or OneStrap, Mitre10 Mega) for optimal fitting 
while maintaining splint aesthetic and integrity. Splint intervention procedure will comprise a 
one-off face-to-face consult anticipated to take maximum 20 minutes per participant and follow a 
1-sided A4 information sheet specific to the left (Supplementary 1) or right (Supplementary 2) 
hand. Participants will be asked to complete a daily log to record  the number of hours 
splint worn and any reasons for not wearing the splint (for those in the intervention group), 
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implementation of usual care, , any concerns or problems, and any change in medication, 
according to a template form (Supplementary3). The 4-week timepoint will mark the end of the 
intervention period. 
Standardised usual care 
Both groups will receive a standardised package of recommended best-practice usual care – 
verbal and written education about thumb CMC OA and joint care principles, simple hand 
exercises, and advice to increase general activity levels (walking or pool) [7] following a 2-sided 
A4 information sheet specific to the left (Supplementary 4) or right (Supplementary 5) hand with 
additional verbal cues (Supplementary 6), plus continue with usual physician care. The same 
behavioural approach will be taken as for the splint intervention. The standardised usual care 
package will be delivered at a one-off face-to-face consult anticipated to take 25 minutes per 
participant, by the same person delivering the intervention (MB). Participants in the no splint 
group will be asked to log daily as above, with the exception of splint wearing 
(Supplementary7). 
If participants in either group require assistance during the 4-week treatment period, they may 
contact the research administrator for the treating therapist to make an arranged call to the 
participant. If any issue is unable to be resolved by telephone consult, then a follow up treatment 
session will be arranged. Participants will not be offered additional treatment after the 4-week 
intervention period is complete; participants randomized to the best-practice usual care group 
will not be offered the splint intervention as there is currently insufficient evidence to 
demonstrate that this intervention is effective.  
At the completion of the 4-week intervention period and following the 4-week follow-up 
assessment, the treating therapist will telephone or email (as preferred) each participant to ask 
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about any adverse events, counsel the participant regarding intervention received by the other 
group, reiterate that the treatment period is complete, and advise that any of the standardized 
usual care and/or splint intervention may be continued at the participant’s discretion.   
Intervention development 
The splint intervention and standardized usual care were developed through two stakeholder 
focus groups (n=6, n=2) and a single one-to-one interview (n=1) run by the first author (MB) 
with experienced Hand Therapy New Zealand-registered hand therapists (physiotherapists and 
occupational therapists) working in public and private practice settings in New Zealand. The 
development of the standardised usual care package was informed by a previously published 
resource widely used in hand therapy clinical practice [35] and best available evidence [36] and 
expert opinion [37] regarding specific exercise programmes for thumb base OA. 
Intervention fidelity 
Measures to optimize adherence to the intervention and standardized usual care include: ensuring 
the splint is comfortable, well fitted and aesthetically acceptable; advising how to successfully 
adapt activities without compromising the splint regime [38]; establishing a trusting relationship 
by providing education and rationale for treatments [39]; catering for different learning styles 
[40]; and implementing simple behavioural intervention [34]. Adherence will be measured by a 
daily patient log – recording splint wearing time in the intervention group and recording uptake 
of standardized usual care in both the intervention and the control group. The clinical research 
administrator will telephone or text reminders (as preferred) on a weekly basis to remind the 




The clinical assessments (secondary outcomes) are a combination of self-reported and 
performance measures. Assessments are collected at baseline, then at 4 weeks and 6 months 
(Table 3). Patient characteristic variables will be collected at baseline (Table 4). Grip strength 
will be measured using the same dynamometer for all assessments for each participant (i.e. one 
dynamometer in Dunedin and one in Invercargill). 
Imaging 
X-ray imaging will occur for each participant to characterise radiological involvement of the CMC 
joint at baseline, unless a recent (< 6 months) X-ray of good quality is available. X-rays will be 
interpreted by a consultant orthopaedic surgeon according to the OARSI-atlas grade for individual 
features (osteophytes and joint space narrowing) [41] and modified Eaton-Littler grade [42], with 
a second independent interpretation by a Professor of Radiology. X-rays may help to identify 
potential factors that predict treatment response. A random selection of X-rays will be repeat read 
by a consultant radiologist.  
Similarly, ultrasound imaging will be performed in a convenience sample of eight participants at 
the Dunedin site. Ultrasound imaging will be undertaken and interpreted independently by two 
consultant rheumatologists (SS) with experience and training in musculoskeletal ultrasound, 
according to a recommended scanning protocol [43], each patient being scanned blind by both 
clinicians.  
Clinicians involved in acquisition and/or reading of X-rays or ultrasound images will be blinded 




Quality of intervention delivery and outcome assessment will be audited using a pre-defined 
quality audit tool based on that used in the OTTER trial [2019 email from fourth author (JA) to 
first author (MB)]. 
Training of independent assessors 
Three independent health research assistants (two in Dunedin and one in Invercargill) will be 
trained to conduct baseline and follow-up outcome assessment according to assessor manual 
(Supplementary 8). Each participant will be assessed by the same assessor at each of the three 
assessment timepoints.  
Statistical analysis 
Data analysis 
Data analysis will comprise descriptive analysis of the feasibility outcomes and appraisal against 
feasibility criteria. Baseline participant characteristics will be presented using descriptive statistics 
(mean, standard deviation and 95% confidence interval). Differences between the groups at 
different time points will be described but formal statistical analysis will not be undertaken due to 
the small sample size.   
Ethics 
This study will be conducted according to good clinical practice guidelines and in compliance 
with the Declaration of Helsinki. Investigators who are also clinician employees of the Southern 
District Health Board (MB, SS and DGJ) will not be involved in gaining consent from potential 
participants to avoid any potential perception of coercion. A $20 petrol voucher along with other 
benefits of involvement in the study including education and advice about thumb base OA, will 
reimburse participants for their costs incurred in attending each of the three assessments. The 
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study has ethical approval from the New Zealand Northern B Health and Disability Ethics 
Committee Ref 18/NTB/240. 
Notification of adverse events 
Participants will be asked to notify the research administrator of any adverse events. These will 
be forwarded to the study treating therapist who will address concerns with the patient by 
telephone in the first instance and in person if necessary and/or refer on for further care. All 
adverse events will be recorded and brought to the study monitoring committee. Splinting is a 
low risk intervention and few adverse events are anticipated. 
Discussion:                                                                     
This study will contribute to a broader programme of OA research that aims to enable equitable 
access to low cost non-surgical, non-pharmacological treatments to improve daily life and 
maintain healthy ageing for people with OA in New Zealand and internationally. The current 
study will provide essential information about the feasibility of conducting a future full-sized 
trial. If shown to be feasible, a subsequent RCT investigating the effectiveness of a soft off-the 
shelf splint as first-line option for managing thumb CMC OA will be undertaken using the 
current protocol with any adaptations resulting from analysis of the feasibility data. The 
contribution of expert clinicians in the study development will enhance relevance and uptake of 
the study findings to the real-world clinical setting. This project embeds methodology that aims 
to ensure participants of Māori descent are included in the generation of new health knowledge, a 
key step in addressing the poor health care utilisation for osteoarthritis by Māori (19). Further, 
the inclusion of participants who have not sought care for their thumb CMC OA will help to 
ensure that findings from the current study are relevant for equitable health outcomes across the 
spectrum irrespective of barriers to accessing health care. Ultimately, findings can inform health 
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funding policy on provision of orthotic devices for people with thumb CMC OA, and clinicians 
will be better informed and more likely to nominate an appropriate intervention for their patients. 
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Figure 1.  Participant flow diagram 
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Table 1 Feasibility trial objectives and primary outcomes 
Study objectives Primary outcomes Feasibility criteria 
1. Recruitment and 
retention: to be able 
to determine the 
number of potential 
participants needed 
to be screened across 




Number screened, number eligible and 
number allocated, over 4-month period or 
until 30 participants are allocated, 
whichever is earlier.  
• Proportion of population coming 
forward 
• Proportion of screened eligible 
• Proportion of eligible allocated 
• Proportion of allocated assessed at 
4 weeks, 6 months 
• No. of days to allocate 30 
participants.  
Recruit 30 participants in 
4-month period. 
Retain >85% of 
participants at 6 months 
2. To determine 
acceptability of 
splint intervention 
Exit interview with participants (qualitative 
data).  
 
≥90% of participants find 
intervention acceptable. 
3. Determine rate of 
adverse events 
Number of major adverse events; rate of 
minor adverse events (type and number of 
events). 






Table 2 Table of inclusion and exclusion 
Inclusion criteria Exclusion criteria 
• Aged 40+ years 
• Physician diagnosis of thumb base OA OR 
answer “yes” to the question, “Have you 
experienced aching, discomfort, pain 
and/or stiffness in or around the joint at 
the base of either thumb on most days for 
at least 1 month (15 or more days of the 
month) during the past year?” and have no 
other specific diagnosis[31]. 
• Minimum severity pain VAS 4/10[44] 
• Minimum score FIHOA 6/30[44] 
• One or more clinical sign(s) of 1st CMC 
joint involvement*. 
• Give written informed consent 
• Thumb non-symptomatic for the past 
month 
• Previous surgery of the symptomatic joint 
• Steroid injection in the past 6 months 
• Previous splint intervention prescribed by 
health professional 
• Concurrent rheumatoid arthritis or any 
other significant musculoskeletal, 
inflammatory or autoimmune conditions 
affecting the hand such as scleroderma, 
systemic lupus erythematosus and 
psoriatic arthritis, or another kind of 
chronic pain syndrome or metabolic 
disorder, such as fibromyalgia, diabetic 
neuropathy, or gout. 
• Injury to thumb/wrist in past 6 months 
• Unable to comprehend instructions and 
outcome measure instruments in English. 




Table 3 Secondary outcome measures 
Assessment – secondary outcomes: Measurement scale: Time*: 
Pain numeric rating scale (NRS) for pain at base of 
thumb, on average in past week 
0-10 0, 4, 26 
Pain at base of thumb interfering with sleep (NRS), on 
average in past week, and dichotomous 
0-10 
Yes / No 
0, 4, 26 
Functional Index of Hand Osteoarthritis (FIHOA) (10 
questions relating to function, rated 0-3; low score is 
better) [45] 
0-30 0, 4, 26 
Additional functional and participation questions (from 
qualitative study [6]) 
0-3 0, 4, 26 
Quick Disability of the Arm, Hand and Shoulder 
(QuickDASH) (11-item questionnaire, rated 0-4; low 
score is better)  
0-100 0, 4, 26 
GROC (Global Rating of Change) -5 to +5 4, 26 
Patient-reported health status (EQ5D) 0.0 – 1.0 0, 4, 26 
NSAID Equivalent score (+/- other medications)  0, 4, 26 
Other interventions sought (including surgery)  4, 26 
Power grip strength, dynamometer (best of three)  Kilogram  0, 4, 26 
Pinch grip strength, dynamometer (best of three) Kilogram  0, 4, 26 
Inter-digit distance (length of 1st webspace, ruler)  mm  0, 4, 26 
CMC joint palmar abduction (Pollexograph – purpose-
built box with protractor printed on top) [46] 
Degrees 0, 4, 26 
Grip Ability Test (GAT) (test of functional performance, 
timed) 
Seconds 0, 4, 26 
OMERACT-OARSI responder [47] Yes / No 4, 26 




Table 4 Participant baseline characteristics 
Participant characteristic variable:  Measurement scale: 
Age years 
Gender male / female / gender diverse 
Ethnicity  
Descent  
Work status Full time / part time / not working / 
student / in the home / unemployed or 
seeking work / age retired / disability 
pension / sick leave 
Dominant hand Left / Right / Ambidextrous 
Hand with thumb CMC OA Left / Right / Both 
Thumb osteoarthritis diagnosed by health care 
provider?   
Yes / No 
If yes, which health care provider?  GP, physio/hand therapy, 
rheumatologist, surgeon 
How long have you had your thumb CMC 
problem(s)? 
years 
Other joints with osteoarthritis (besides your hands):  
Other medical conditions  (e.g. rheumatoid arthritis, other arthritis, 
gout, diabetes, heart problems) 
Current medications   
Current and previous treatments for thumb CMC 
problem 
 
Thumb MCP hyperextension at rest degrees 
Joint tenderness on palpation* Present / absent 
Grind test* [48] Positive / negative 
Pressure-shear test* [49] Positive / negative 




X-ray: standard PA view, OARSI-atlas grade for 
individual features (osteophytes, JSN) [41]; Eaton-




Ultrasound: grade for synovitis and osteophytes ;  0-3 semi-quantitative scale, and 
dichotomous “Present / Not present” 
* Clinical tests for 1st CMC joint involvement – one or more are positive for inclusion (see Table 
2) 
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